BioInvent International AB (OSTO:BINV) EV-to-EBIT : -3.39 (As of May. 30, 2025)

View and export this data going back to 2001. Start your Free Trial

What is BioInvent International AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BioInvent International AB's Enterprise Value is kr1,707.74 Mil. BioInvent International AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was kr-504.13 Mil. Therefore, BioInvent International AB's EV-to-EBIT for today is -3.39.

The historical rank and industry rank for BioInvent International AB's EV-to-EBIT or its related term are showing as below:

OSTO:BINV' s EV-to-EBIT Range Over the Past 10 Years
Min: -43.65 Med: -4.71 Max: 0.54
Current: -3.38

During the past 13 years, the highest EV-to-EBIT of BioInvent International AB was 0.54. The lowest was -43.65. And the median was -4.71.

OSTO:BINV's EV-to-EBIT is ranked worse than
100% of 473 companies
in the Biotechnology industry
Industry Median: 8.26 vs OSTO:BINV: -3.38

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. BioInvent International AB's Enterprise Value for the quarter that ended in Mar. 2025 was kr1,299.74 Mil. BioInvent International AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was kr-504.13 Mil. BioInvent International AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -38.79%.

BioInvent International AB EV-to-EBIT Historical Data

The historical data trend for BioInvent International AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB EV-to-EBIT Chart

BioInvent International AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-EBIT

Get a 7-Day Free Trial

-14.34

-5.93

-26.08

-0.61

-3.93

BioInvent International AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial															-0.20	-3.33	-4.92	-3.93	-2.58

Competitive Comparison of BioInvent International AB's EV-to-EBIT

For the Biotechnology subindustry, BioInvent International AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioInvent International AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

BioInvent International AB EV-to-EBIT Calculation

BioInvent International AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1707.739	/	-504.133
	=	-3.39

BioInvent International AB's current Enterprise Value is kr1,707.74 Mil.
BioInvent International AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-504.13 Mil.

BioInvent International AB (OSTO:BINV) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

BioInvent International AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 )	=	EBIT	/	Enterprise Value (Q: Mar. 2025 )
	=	-504.133	/	1299.7412
	=	-38.79 %

BioInvent International AB's Enterprise Value for the quarter that ended in Mar. 2025 was kr1,299.74 Mil.
BioInvent International AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-504.13 Mil.

BioInvent International AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BioInvent International AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (OSTO:BINV) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

0H22:UK BIX0:Germany

Address

Ideongatan 1, Lund, SWE, SE-223 70

Website

https://www.bioinvent.com

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.